Compare IMCR & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMCR | GLUE |
|---|---|---|
| Founded | 2008 | 2019 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 2016 | 2021 |
| Metric | IMCR | GLUE |
|---|---|---|
| Price | $26.33 | $8.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 10 |
| Target Price | ★ $59.30 | $25.38 |
| AVG Volume (30 Days) | 414.0K | ★ 1.2M |
| Earning Date | 11-06-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.39 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $249,428,000.00 | $123,672,000.00 |
| Revenue This Year | $9.28 | N/A |
| Revenue Next Year | $9.91 | N/A |
| P/E Ratio | ★ N/A | $72.42 |
| Revenue Growth | 43.05 | ★ 63.54 |
| 52 Week Low | $26.53 | $8.75 |
| 52 Week High | $40.71 | $25.77 |
| Indicator | IMCR | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 32.57 | 26.87 |
| Support Level | N/A | N/A |
| Resistance Level | $31.75 | $12.00 |
| Average True Range (ATR) | 1.46 | 0.58 |
| MACD | -0.46 | -0.12 |
| Stochastic Oscillator | 9.12 | 5.40 |
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).